Western Blot: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Western Blot Analysis of human brain tissue lysate using UCH-L1/PGP9.5 Antibody (31A3)
Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Immunofluorescence Analysis of T98G cells labeling Pgp9.5 with UCH-L1/PGP9.5 Antibody (31A3) followed by Goat anti-Mouse IgG-CF488 ...read more
Immunohistochemistry-Paraffin: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Formalin-fixed, paraffin-embedded human brain stained with UchL1 antibody (PGP9.5) (1:500), peroxidase-conjugate and DAB chromogen. Staining ...read more
Flow Cytometry: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Flow Cytometric Analysis of T98G cells using UCH-L1/PGP9.5 Antibody (31A3)followed by Goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).
Western Blot: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - analysis of UchL1 in 1) human, 2) mouse and 3) rat brain lysate using UchL1 antibody at 1 ug/ml. goat anti-mouse Ig HRP secondary antibody and ECL substrate ...read more
Immunocytochemistry/ Immunofluorescence: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - analysis of PGP9.5 in rat mesenteric artery using anti-PGP9.5 antibody. Image from verified customer review.
Simple Western: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Simple Western lane view shows a specific band for PGP9.5 / UCHL-1 in 0.2 mg/ml of h. Cerebellum (left) and IMR-32 (right) lysate(s). This experiment was ...read more
Simple Western: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Electropherogram images of the corresponding Simple Western lane. PGP9.5 / UCHL-1 antibody was used at 10 ug/ml dilution of h. Cerebellum and IMR-32 ...read more
Native UchL1 (PGP9.5) protein from brain was used as immunogen to generate the antibody (Day & Thompson, 1986).
Cytoplasmic, Endoplasmic Reticulum membrane
This MAb reacts with a protein of 20-30kDa, identified as PGP9.5, also known as ubiquitin carboxyl-terminal hydrolase-1 (UchL1). Initially, PGP9.5 expression in normal tissues was reported in neurons and neuroendocrine cells but later it was found in distal renal tubular epithelium, spermatogonia, Leydig cells, oocytes, melanocytes, prostatic secretory epithelium, ejaculatory duct cells, epididymis, mammary epithelial cells, Merkel cells, and dermal fibroblasts. Furthermore, immunostaining for PGP9.5 has been shown in a wide variety of mesenchymal neoplasms as well. A mutation in PGP9.5 gene is believed to cause a form of Parkinson's disease.
Protein A or G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Human Chromosome Location: 4p13 Immunohistochemistry (Formalin-fixed) (1-2ug/ml for 30 minutes at RT)(Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95 degrees C followed by cooling at RT for 20 minutes). Optimal dilution for a specific application should be determined. This antibody has been reported to work in IHC-Frozen as reported in the literature (Bottner et al. Drew et al.) and (Sugimoto et al. J Hyperten).
In Simple Western only 10 - 15 uL of the recommended dilution is used per data point. Separated by Size. The 7mL size is a pre-diluted size and no additional dilutions are required before using this item for the intended application.
25 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
UchL1 (ubiquitin C-terminal hydrolase), also known as PGP9.5 (protein gene product 9.5) and PARK5, is a neuronal biomarker and ubquitin system protein (reviewed in Day and Thompson, 2010). UchL1 is a highly conserved antibody and has shown that it is expressed in neurons and neuroendocrine cells in vertebrates where it comprises about 5-10% of soluble cytoplasmic proteins. A minor proportion of UchL1 in brain is tightly bound to the membrane. UchL1 antibody is also expressed in human oocytes and spermatogonia. It is important to note that the use of an antibody as a biomarker in this case does not imply that an antibody defines absolute tissue specificity. Rather, it means that PGP9.5 is expressed in neurons and neuroendrocine cells at significantly higher levels than in other cell types. Functionally, UchL1 antibody is a thiol protease enzyme that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin. UchL1 antibody also binds to free monoubiquitin and inhibits monoubiquitin degradation in lysosomes; it may function to stabilize monoubiquitin within neurons. A mutation in the UchL1 gene has been found to cause a form of Parkinson's disease, and this discovery has spurred considerable research interest in UchL1 and to its alternative name of PARK5. Antibody to UchL1 is widely used as an immunohistochemical marker of nerves and neuroendocrine cells. The UchL1 clone 31A3 antibody stains neuronal cell bodies and axons in the central and peripheral nervous systems as well as small nerve fibers in peripheral tissues, including epidermal tissues (Day & Thompson, 2010). The antibody also stains neuroendrocrine cells in the kidney, pituitary, thyroid, pancreas, gastrointestinal tract, and tumors of the diffuse neuroendocrine system. This antibody has also identified UchL1 expression in renal tubule spermatogonia, testis, ovary, and both pregnant and non-pregnant corpus luteum. In western blots, the antibody identifies UchL1 as a band of approximately 20-30 kDa. The antibody is specific to UchL1 and does not cross-react with the closely related UchL3 protein (Yi et al, 2007).
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.